{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-060462","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.220764+00:00","generated_at":"2026-06-01T22:48:40.581110+00:00","sec_items":["5.02","5.07","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Syndax appoints Aleksandra Rizo to Board; Morrison resigns; annual meeting votes passed","bullets":["Aleksandra Rizo, M.D., Ph.D., elected to Board effective May 15, replacing Briggs Morrison who resigned.","Dr. Rizo receives $45,644 annual cash for Board service, $8,558 for Science & Technology Committee, plus initial option for 35,000 shares vesting monthly over three years.","Annual meeting results: all director nominees elected (Huber 61.9M for, Jarrett 39.5M for), executive compensation advisory vote passed (46.2M for, 16.3M against), auditor ratified (65.4M for).","Dr. Rizo is President/CEO of Vividion, brings hematology clinical development and regulatory experience."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-060462","json":"https://secwatch.observer/filing/0000950170-24-060462.json","markdown":"https://secwatch.observer/filing/0000950170-24-060462.md","text":"https://secwatch.observer/filing/0000950170-24-060462.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000095017024060462/0000950170-24-060462-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000095017024060462/sndx-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:48:40.581110+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a0711d0abb","claim":"Aleksandra Rizo was elected as Director at Syndax Pharmaceuticals Inc.","evidence_excerpt":"On May 15, 2024, the Board of Directors (the “ Board ”) of Syndax Pharmaceuticals, Inc. (the “ Company ”), unanimously voted to elect Aleksandra Rizo, M.D., Ph.D. to the Board, effectively immediately","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017024060462/0000950170-24-060462-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}]},{"claim_id":"ff98744132","claim":"Briggs W. Morrison resigned as Director at Syndax Pharmaceuticals Inc.","evidence_excerpt":"On May 14, 2024, Briggs W. Morrison, M.D. advised the Board that he will resign from his position as a Class III member of our Board effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017024060462/0000950170-24-060462-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}]},{"claim_id":"57bdab553062312b58247b2d0511f6e867e204a0","claim":"Syndax Pharmaceuticals Inc shareholders approved Election of directors at the 2024-05-15 meeting.","evidence_excerpt":"Proposal 1 : Election of directors: Nominee For Withheld Broker Non-Votes Martin H. Huber, M.D. 61,876,711 736,625 3,032,770","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017024060462/0000950170-24-060462-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-15"}]},{"claim_id":"e99f9eed9b51e44ca8e69d1954c07fc2368cafd1","claim":"Syndax Pharmaceuticals Inc shareholders approved Advisory vote on executive compensation at the 2024-05-15 meeting.","evidence_excerpt":"Proposal 2 : Advisory vote on executive compensation: For Against Abstain Broker Non-Votes 46,228,421 16,304,796 80,119 3,032,770","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017024060462/0000950170-24-060462-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-15"}]},{"claim_id":"f8ae3d8b954dd73ef860e133e0faedf2ee8c7b64","claim":"Syndax Pharmaceuticals Inc shareholders approved Ratification of selection of independent registered public accounting firm at the 2024-05-15 meeting.","evidence_excerpt":"Proposal 3 : Ratification of selection of independent registered public accounting firm: For Against Abstain Broker Non-Votes 65,371,337 253,270 21,499 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017024060462/0000950170-24-060462-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-15"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}